Sneha Girap (Editor)

Arie Belldegrun

Updated on
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Citizenship  Israeli and American
Name  Arie Belldegrun
Years active  1988-present
Role  Businessman

Religion  Jewish
Spouse  Rebecka Belldegrun
Children  4
Arie Belldegrun filesshareholdercomdownloadsAMDA2V2XOY0x0x76
Born  1949 (age 65–66)Israel
Alma mater  Hadassah Medical CenterWeizmann Institute of Science
Occupation  Chairman, President and CEO of Kite Pharma
Education  Weizmann Institute of Science
Residence  Los Angeles, California, United States

Organizations founded  Kite Pharma

Ucla researcher dr arie belldegrun on kidney cancer

Arie S. Belldegrun (born 1949) is an Israeli-born American urologic oncologist, businessman, and investor.


Arie Belldegrun 2dvvgi2jq0x81blzoq11w0qxwpenginenetdnacdncomw

Arie Belldegrun Keynote Yale Innovation Summit 2018

Early life and academia

Arie Belldegrun Arie Belldegrun Alchetron The Free Social Encyclopedia

Belldegrun was born in Israel. He received his medical degree from the Hadassah Medical Center at Hebrew University of Jerusalem in 1974, and conducted his post-graduate studies at the Weizmann Institute of Science in 1979. He completed his Urologic Surgery residency at Harvard Medical School in 1985, and his Surgical Oncology fellowship at the National Cancer Institute in 1988. He is certified by the American Board of Urology, and is a fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons. Belldegrun is the Director of the UCLA Institute of Urologic Oncology, Professor of Urology, and Chief of the Division of Urologic Oncology at the David Geffen School of Medicine.


Arie Belldegrun Arie Belldegrun MD FACS Two River Two River

In 1996, Belldegrun established Agensys, an early-stage privately held biotechnology company based in Los Angeles, that is focused on the development of fully human monoclonal antibodies to treat solid tumor cancers in a variety of cancer targets. He served as its founding Chairman of the Board of Directors from 1996 to 2002, and then as a Director until December 2007, when Agensys was acquired by Astellas Pharma in a deal valued at $537 million.

Cougar Biotechnology

Arie Belldegrun Arie Belldegrun Alchetron The Free Social Encyclopedia

Belldegrun has been a founding Vice Chairman of the Board of Directors and Chairman of the Scientific Advisory Board of Cougar Biotechnology since 2003, a Los Angeles-based company with a focus in the field of oncology. In July 2009, the company was acquired by Johnson & Johnson in a $970 million transaction. In April 2011, the United States Food and Drug Administration approved Abiraterone Acetate (Zytiga), Cougar’s lead product, for late stage prostate cancer.

Two River

Since 2008, Belldegrun has been the Chairman and Partner of Two River, a New York-based venture capital firm and merchant bank focused on the life science sector. It specializes in investments in life science, biotechnology, and in firms focused on developing preventative and therapeutic technologies for a broad spectrum of disease areas including oncology, cardiovascular disease, neurological disorders, and companion animal health care.

Kite Pharma

Belldegrun is the Chairman, President and CEO of Kite Pharma (NASDAQ: KITE) which he founded in 2009. Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous T cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. The company went public in June 2014. Belldegrun, who owns 6.38 million shares of the company, has a stake worth over $400 million today. On August 28, 2017, the biopharmaceutical firm Gilead to buy the Israeli-founded Kite Pharma for nearly $12 billion USD an all-cash deal.

Other board memberships

Belldegrun also serves as a member of the following boards:

  • Arno Therapeutics (OTCBB: ARNI) - Chairman (since March 2008)
  • UroGen Pharma (formerly TheraCoat) - Chairman (since October 2012)
  • Cell Design Labs - Director
  • Oncura - Chairman of the Medical Advisory Board
  • Roei Medical Technologies - Chairman of the Medical Advisory Board
  • Pontifax - Chairman
  • LSM at the University of Pennsylvania - Member of the Advisory Board
  • In the past, Belldegrun served as a member of a number of boards, including:

  • Teva (NYSE: TEVA) - Director and Vice Chairman of the Science & Technology Committee (February 2013 to January 2017)
  • SonaCare Medical (formerly Ushifu) - Director and Urological Advisor (September 2009 to 2014)
  • Capricor Therapeutics (formerly Nile Therapeutics) - Director (September 2009 to November 2013)
  • Talon Therapeutics (formerly Hana Biosciences) - Director, Chairman of the Compensation Committee and member of the Nominating & Governance Committee (April 2004 to December 2009)
  • Paramount Acquisition - Director (June 2005 to January 2008)
  • Chem Rx Corporation - Director (June 2005 to January 2008)
  • RENCAREX at Wilex AG - Chairman of the Medical Advisory Board
  • Email Real - Director
  • Recent business

  • In May 2013, TheraCoat, a clinical stage specialty pharmaceutical company of which Belldegrun is the Chairman, has raised $7 million in capital from private investors and venture funds.
  • Also in May 2013, Kite Pharma completed a $35 million financing of Series A preferred stock.
  • In October 2013, Arno Therapeutics completed a $30.7 million financing of equity.
  • In November 2013, Nile Therapeutics completed a merger with Capricor to form Capricor Therapeutics (OTCBB: CAPR). Capricor has become a wholly owned subsidiary of Nile.
  • In February 2014, Velcera, a portfolio company of Two River, was acquired by Perrigo for $160 million.
  • In June 2014, Kite Pharma sold 8,625,000 shares in their IPO at $17.00 per share, for net proceeds of $134.1 million. The company listed on the NASDAQ Global market under the symbol “KITE.”
  • In May 2015, it was announced that TheraCoat is seeking to raise more than $20 million in the coming months as it prepares for an initial public offering in New York. The company will seek a valuation of about $200 million in the IPO.
  • In January 2016, Arno Therapeutics completed a $7.4 million financing of equity.
  • In August 2016, Arno Therapeutics completed a $2.8 million private placement of its common stock.
  • In April 2017, UroGen Pharma (formerly TheraCoat) filed with the US Securities and Exchange Commission (SEC) to raise up to $50 million in an IPO on NASDAQ. The company's value has not yet been disclosed. The company plans to list on the NASDAQ under the symbol URGN. Jefferies and Cowen & Company are the joint bookrunners on the deal.
  • Personal life

    Belldegrun is married to Dr. Rebecka Belldegrun and together they have four children. They reside in Bel Air, an affluent neighborhood in Los Angeles. Their oldest son, Ben Belldegrun, a hedge fund manager, is married to Kelly Bergantz, senior producer for Syco.

    In 2014, according to the Bloomberg Pay Index, Belldegrun was ranked the 8th highest-paid executive in the United States, with a pay package valued at $95.2 million.

    In 2015, The Hollywood Reporter's annual Hollywood's Top Doctors list included Belldegrun as one of the highest-rated urologists.

    In 2016, in its annual ranking of the wealthiest people in Israel, Forbes Israel ranked Arie and Rebecka Belldegrun 37th with a personal net worth of ₪3.9 billion (equal to US$1 billion).

    Belldegrun has written over 400 scientific publications related to urologic oncology, and has authored several books on prostate and kidney cancers. He was one of the speakers at the Milken Institute Global Conference 2013, delivered the keynote Andrew C. Novick Memorial Lecture at the Ninth International Kidney Cancer Symposium, and regularly presents at the Annual J.P. Morgan Healthcare Conference. It was announced that Belldegrun will present at the 34th Annual J.P. Morgan Healthcare Conference in January 2016.

    Arie and Rebecka Belldegrun have donated over $1 million to the University of Pennsylvania School of Arts and Sciences, and have donated a $5 million sculpture to LACMA.


    Arie Belldegrun Wikipedia